Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Equity Ratio (2018 - 2025)

Addex Therapeutics' Equity Ratio history spans 8 years, with the latest figure at 0.75 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 17.35% to 0.75 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.75, a 17.35% decrease, with the full-year FY2025 number at 0.75, down 17.35% from a year prior.
  • Equity Ratio came in at 0.75 for Q4 2025, down from 0.91 in the prior quarter.
  • The five-year high for Equity Ratio was 0.91 in Q4 2024, with the low at 0.25 in Q4 2023.
  • Historically, Equity Ratio has averaged 0.65 across 5 years, with a median of 0.75 in 2025.
  • Biggest five-year swings in Equity Ratio: crashed 58.4% in 2023 and later skyrocketed 267.25% in 2024.
  • Year by year, Equity Ratio stood at 0.75 in 2021, then fell by 21.02% to 0.59 in 2022, then tumbled by 58.4% to 0.25 in 2023, then soared by 267.25% to 0.91 in 2024, then fell by 17.35% to 0.75 in 2025.
  • Business Quant data shows Equity Ratio for ADXN at 0.75 in Q4 2025, 0.91 in Q4 2024, and 0.25 in Q4 2023.